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Abstract
Background: Intensive insulin therapy to maintain normoglycemia after cardiac surgery reduces
morbidity and mortality. We investigated the magnitude and duration of hyperglycemia caused by
dexamethasone administered after cardiopulmonary bypass.
Methods: A single-center before-after cohort study was performed. All consecutive patients
undergoing coronary artery bypass grafting with cardiopulmonary bypass during a 6-month period
were included. Insulin administration was guided by a sliding scale protocol. Halfway the
observation period, the dexamethasone protocol was changed. The single dose (1D) group
received a pre-operative dose of dexamethasone of 1 mg/kg. The double dose group (2D) received
an additional dose of 0.5 mg/kg of dexamethasone post-operatively at ICU admission.
Results: We included 116 patients in the 1D group and 158 patients in the 2D group. There were
no significant baseline differences between the groups. Median Euroscore was 5. In univariable
analysis, the glucose level was different between groups 1D and 2D at 4, 6, 9, 12 and 24 hours after
ICU admission (all p < 0.001). Insulin infusion was higher in the 1D group. Corrected for insulin
dose in multivariable linear analysis, the difference in glucose between the 1D and 2D groups was
1.5 mmol/L (95% confidence interval 1.0–2.0, p < 0.001) 12 hours after ICU admission.
Conclusion: Dexamethasone exerts a hyperglycemic effect in cardiac surgery patients. Patients
receiving high-dose corticosteroid therapy should be monitored and treated more intensively for
hyperglycemic episodes.
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Background
Cardiac surgery with cardiopulmonary bypass induces a
strong systemic inflammatory response in previously
healthy individuals [1]. This response is characterized by
changes in cardiovascular and pulmonary function [2-4].
Corticosteroids inhibit this inflammatory response and
may thus ameliorate the adverse effects of cardiopulmo-
nary bypass [1,5,6]. High-dose dexamethasone is one of
the therapies given in some centers to reach this effect.
However, corticosteroid use in cardiac surgery is contro-
versial, because important side effects may result [7]. One
of the side effects is increased insulin resistance, which
causes hyperglycemia [8]. The emerging evidence on neg-
ative effects of dexamethasone has prompted a protocol
change in our institution.
In patients with myocardial infarction, prolonged hyperg-
lycemia after admission is associated with adverse out-
come [9,10]. Glycometabolic dysregulation is common in
patients undergoing cardiac surgery [11]. Tight glucose
control with intensive insulin therapy has been shown to
decrease mortality and morbidity in these patients [12]. In
patients undergoing coronary artery bypass grafting, the
survival benefit persisted at 4 years follow-up [13]. As the
benefits of insulin therapy are related to the level of
achieved glucose control, the impact of corticosteroids on
hyperglycemia has become more relevant [14]. We
hypothesized that a reduction of dexamethasone dose
would facilitate glucose control. We performed a before-
after study to quantify the hyperglycemic effect of a sec-
ond dose of dexamethasone administered post-
operatively at the intensive care unit (ICU) in patients
undergoing coronary artery bypass surgery (CABG) with
cardiopulmonary bypass.
Methods
This study was performed at a 14-bed thoracic ICU in a
tertiary teaching hospital. During a 6 month period (from
April to October 2005) all patients undergoing CABG
with the use of cardiopulmonary bypass were studied.
Both patients with only CABG and CABG with additional
valve repair were included. During the 6-month observa-
tion period, the treatment protocol was modified by the
medical staff. Before the change, all patients were admin-
istered 1.0 mg of dexamethasone per kilogram of body
weight at the induction of anesthesia and a second dose of
0.5 mg/kg at admission to the ICU. The patients in this
dosing scheme were in the double-dose (2D) group. After
the change, the second dose was withheld, so patients
only received the initial 1.0 mg/kg dose (group 1D). The
protocol change was made after a previous study, in which
high-dose dexamethasone failed to provide a beneficial
effect on peri-operative renal function [15] and review of
other available evidence [7]. The institutional review
board approved this study.
At baseline, we collected demographic and clinical infor-
mation, including sex, age, body mass index (BMI) and
presence of diabetes before hospital admission. Operative
risk stratification was done by means of the EuroSCORE
model [16]. Time on cardiopulmonary bypass and total
operation time were recorded. During the ICU stay, we
collected blood glucose levels, and insulin administration
for the first 48 hours. Glucose levels were measured in
arterial blood samples using a point-of-care blood gas
analyzer present at the ICU (ABL Radiometer 700 series,
Copenhagen). Insulin was administered according to a
sliding-scale insulin dosing algorithm. The algorithm was
designed to treat hyperglycemia defined as a glucose
level over 10 mmol/L but did not aim for normoglycemia
(4.4 – 6.1 mmol/L). Our protocol prescribed a 1 liter infu-
sion of glucose 5% during the first 24 hours.
For data processing and statistical analysis SPSS version
12.0 was used. Baseline characteristics of the two groups
were expressed as mean ± standard deviation (SD) for nor-
mally distributed variables or as median (interquartile
range, IQR) for other variables. We compared differences
between groups with the Student's t-test for normal dis-
tributed variables or the Mann-Whitney U test for other
continuous variables. For categorical variables, the Chi-
square test or Fisher's exact test were used when appropri-
ate. We analyzed the blood glucose levels at 2, 4, 6, 9, 12,
24 and 48 hours after ICU admission for each patient. The
glucose values at these specific times were calculated by
linear interpolation. We also calculated the hyperglycemic
index for the first 12 hours after admission [17].
The time course of glucose levels was compared with uni-
variable analysis between groups 1D and 2D to determine
if and when glucose levels diverged between the two
groups. It was then determined at what time the difference
in glucose was greatest between the two groups. To assess
the relative contributions of patient group (1D or 2D),
age, sex, diabetes, BMI and insulin administration to this
maximum difference in glucose, we performed multivari-
able linear regression analysis. We included variables in
the model that had a univariable p-value smaller than
0.15. Differences or statistical relations with a p-value of
less than 0.05 were considered significant. Bonferroni's
correction for multiple testing was applied where
appropriate.
Results
A total of 274 patients were included in this study, 116 in
the 1D-group and 158 patients in the 2D-group. Table 1
shows the patient characteristics at baseline for both
groups. The mean age of the population was 69 ± 9 years,
and 70% of them were male. Median ICU length of stay
was 1.0 (0.8–1.8) days and the hospital length of stay was
12 (9–16) days. Pre-operative risk scoring shows that 36%Cardiovascular Diabetology 2007, 6:39 http://www.cardiab.com/content/6/1/39
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of the population was at medium risk (EuroSCORE 3–5),
and 42% was at high risk (EuroSCORE > 5). Thirty-day all
cause mortality was 3.3%. The operation time was slightly
longer in the 1D group.
Figure 1 shows the mean and standard deviation of blood
glucose levels over the first 48 hours after ICU admission.
At 4, 6, 9, 12 and 24 hours after admission glucose levels
were significantly lower in the 1D-group than in the 2D-
group, with the greatest difference at 12 hours. The hyper-
glycemic index over the first 12 hours was significantly
lower in the 1D group: 3.5 ± 1.4 mmol/L vs. 4.7 ± 1.7
mmol/L (p < 0.001). Performance and attention for the
glucose control protocol improved during the study
period. Patients in the 1D group received 26 (15 – 36)
units of insulin during the first 12 hours of ICU stay, for
the 2D group this was 12 (0 – 27.25, p < 0.001). The
number of glucose measurements in the first 12 hours was
6 (4 – 7) in the 1D group and 4 (3 – 5) in the 2D group.
Figure 2 shows the glucose level 12 hours after admission
for both groups stratified for mean insulin infusion rate
during the first 12 hours. In multivariable linear regres-
sion analysis, the attributable increase of glucose at 12 h
after admission was 1.5 mmol/L for a second dose of dex-
amethasone (p < 0.001, table 2). The difference in glucose
levels between the 1D and 2D groups was similar in
patients with and without a history of diabetes.
Discussion
In this study we found that cardiac surgical patients who
received two doses of dexamethasone displayed higher
blood glucose levels between 6 and 24 hours after ICU
admission than patients who received one dose of dexam-
ethasone.
High dose dexamethasone is a controversial therapy in
cardiac surgery patients. Both studies that favor the use of
corticosteroids [5] or studies that show some benefit [6] as
well as studies that show no benefit [7,15,18] have been
published. The effect of steroids on glucose control may
be of interest, because high glucose levels are common
and have been shown to be independent predictors of
adverse outcome during cardiac surgery [11,19]. Treat-
ment of hyperglycemia by continuous insulin infusion
has recently been shown to improve outcome [12,13,20].
The difference of 1.5 mmol/L in glucose levels we found
in multivariable analysis is clinically relevant considering
a post-hoc analysis found that the odds ratio for ICU mor-
tality for every increase in glucose level of 1.1 mmol/L is
1.3 [14]. Our study was not powered to detect a difference
in mortality.
While the merit of steroids for cardiopulmonary bypass
may be disputed, steroids are administered for many
other indications in other critically ill patients. For
instance, lower dose corticosteroids may be used to pre-
vent atrial fibrillation after cardiac surgery [21]. For other
patient categories, effects on glucose control have recently
been shown for hydrocortisone in patients with septic
shock [22], or for dexamethasone against nausea in
abdominal surgery patients [23].
A number of limitations of our study must be mentioned.
First, we had not implemented a tight glucose control pro-
tocol at the thoracic ICU at the time of this study. There-
fore, overall glucose control was not comparable to the
levels achieved in intervention studies, reflected by the
HGI which indicates mean glucose levels of 9.5 and 10.7
mmol/L for the groups respectively. We think this does
not change our conclusion that dexamethasone induces
hyperglycemia, as we hypothesize that under a tight glu-
cose control protocol, we would have found that the 1D
group would require less interventions and lower doses of
insulin than the 2D group to achieve the same glucose tar-
gets. Second, although data collection was prospective,
the study as a whole must be regarded as a retrospective
Table 1: Patient characteristics. Characteristics of the two patient groups. 1D: single dose group, 2D: double dose group. Values are 
mean ± standard deviation or median (IQR). CPB: cardiopulmonary bypass.
1D group 2D group p value
N 116 158
Male sex 84 (72%) 108 (68%) NS
Age (years) 68 ± 10 69 ± 8 NS
Diabetes mellitus 33 (28%) 36 (23%) NS
Body mass index 27.4 ± 3.4 27.6 ± 3.9 NS
EuroSCORE 5 (2 – 7) 5 (3 – 7) NS
Other than isolated CABG 32 (28%) 33 (21%) NS
Emergency procedure 3 (3%) 7 (5%) NS
Number of anastomoses 3 (2 – 4) 3 (2 – 4) NS
Time on CPB (hours) 1.8 (1.3 – 2.7) 1.6 (1.4 – 2.3) NS
Operation time (hours) 5.5 (4.6 – 6.4) 5.0 (4.3 – 5.9) .01
30-day mortality 3 (2.6%) 6 (3.8%) NSCardiovascular Diabetology 2007, 6:39 http://www.cardiab.com/content/6/1/39
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study. Bias could have been introduced in our data in a
number of ways. Inherent to the before-after design the
patients were not randomly allocated to the two dosing
groups. A very important variable, insulin infusion, was
found to be significantly different between the two
groups. The multivariable analysis incorporating this and
other possible confounding factors confirmed the highly
significant relation of glucose levels with the administra-
tion of one or two dexamethasone doses. This analysis
may still overestimate the difference caused by dexameth-
asone due to unknown confounding factors and due to
non-linear effects of the included variables. Not all cardiac
surgery centers use dexamethasone as routine treatment in
all cardiac surgery patients. This may be a limitation to the
relevance of our study. However, it is unlikely that the
hyperglycemic effect we measured in this study is unique
to dexamethasone or cardiac surgery patients. Our find-
ings may be extrapolated to the majority of patients
receiving corticosteroids in the intensive care setting.
Although we did not study the effect of giving dexameth-
asone compared to no dexamethasone is this study, the
first dose of dexamethasone also induced considerable
insulin resistance as we have observed in a previous study
[18]. Withholding of the dose administrated upon induc-
tion of anesthesia could further improve glucose control
Time course of glucose levels after ICU admission Figure 1
Time course of glucose levels after ICU admission. Comparison of post-cardiac surgery hyperglycemia for the single 
dose group (1D group, triangles, 116 patients) and for the double dose group (2D group, circles, 158 patients). Data are medi-
ans and interquartile ranges. The glucose level was higher at 4, 6, 9, 12, and 24 hours in the 2D group (all p < 0.001, after 
Bonferroni correction for multiple testing). The difference was largest at 12 hours after ICU admission.Cardiovascular Diabetology 2007, 6:39 http://www.cardiab.com/content/6/1/39
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around the time of ICU admission. This quantitative
study shows that one should be prepared to administer
higher doses of insulin when using dexamethasone in car-
diac surgery patients. In three ICUs in our hospital, we
have implemented a computerized glucose control sys-
tem. We designed this system so that patients who receive
steroids both get higher initial insulin doses, and are
checked more frequently to promptly detect hyperglyc-
emia [24]. Future research on the value of corticosteroids
during cardiac surgery or for other indications in the ICU
should pay very close attention to the hyperglycemic
effects of these drugs. If glucose control is not performed
Glucose levels at 12 hours post ICU admission stratified for mean insulin dose before that time Figure 2
Glucose levels at 12 hours post ICU admission stratified for mean insulin dose before that time. White bars represent the 1D 
group, gray bars represent the 2D group.
Table 2: Linear analysis of determinants of glucose level. Parameters in the linear model predicting glucose level 12 hours after 
admission. CI: confidence interval. *: p < 0.05. +: p < 0.001.
Parameter Univariable coefficient (95% CI) Multivariable coefficient (95% CI)
Age (per year) 0.04 (0.01 to 0.07)+ 0.05 (0.03 to 0.07)+
Male sex NS
History of diabetes NS
Body mass index NS
Other than isolated CABG -0.63 (-1.25 to -0.01)* NS
Emergency procedure NS
EuroSCORE NS
Time on CPB -0.51 (-0.83 to -0.19)+ NS
Operation time -0.32 (-0.51 to -0.13)+ NS
Insulin in the first 12 hours (units) -0.033 (-0.045 to -0.021)+ -0.024 (-0.036 to -0.012)+
2D vs 1D group 1.8 (1.3 to 2.3)+ 1.5 (1.0 to 2.0)+Cardiovascular Diabetology 2007, 6:39 http://www.cardiab.com/content/6/1/39
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adequately, potential positive effects of steroids could be
offset by iatrogenic hyperglycemia.
In summary, the administration of dexamethasone exerts
a considerable hyperglycemic effect in cardiac surgery
patients, interfering with glucose control.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors were involved in drafting the manuscript. All
authors read and approved the final version. MH, JD, MJ
and MN collected data. PB provided EuroSCORE data.
MV, IvdH, FZ, BL and MN designed the study. MV and MN
performed statistical analyses. MN coordinated the study.
Acknowledgements
The authors would like to acknowledge Dr. Wim Sluiter for expert statis-
tical advice.
References
1. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ,
Hart JC, Herrmann HC, Hillis LD, Hutter AM, Lytle BW, Marlow RA,
Nugent WC, Orszulak TA, American College of Cardiology, Ameri-
can Heart Association: ACC/AHA 2004 guideline update for
coronary artery bypass graft surgery: a report of the Ameri-
can College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Update the
1999 Guidelines for Coronary Artery Bypass Graft Surgery).
Circulation 2004, 110(14):e340-e437.
2. Murphy GJ, Angelini GD: Side effects of cardiopulmonary
bypass: what is the reality?  J Card Surg 2004, 19(6):481-488.
3. Kusumanto YH, Tio RA, Loef BG, Sluiter WJ, Mulder NH, Hospers
GA: Systemic VEGF levels after coronary artery bypass graft
surgery reflects the extent of inflammatory response.  Acute
Card Care 2006, 8:41-45.
4. Nathoe HM, van Dijk D, Jansen EW, Suyker WJ, Diephuis JC, van
Boven WJ, De la Rivière AB, Borst C, Kalkman CJ, Grobbee DE,
Buskens E, De Jaegere PP, Octopus Study Group: A comparison of
on-pump and off-pump coronary bypass surgery in low-risk
patients.  N Engl J Med 2003, 348(5):394-402.
5. Yared JP, Starr NJ, Torres FK, Bashour CA, Bourdakos G, Piedmonte
M, Michener JA, Davis JA, Rosenberger TE: Effects of single dose,
postinduction dexamethasone on recovery after cardiac sur-
gery.  Ann Thorac Surg 2000, 69(5):1420-1424.
6. Halvorsen P, Raeder J, White PF, Almdahl SM, Nordstrand K,
Saatvedt K, Veel T: The effect of dexamethasone on side effects
after coronary revascularization procedures.  Anesth Analg
2003, 96(6):1578-83.
7. Chaney MA: Corticosteroids and cardiopulmonary bypass: a
review of clinical investigations.  Chest 2002, 121(3):921-931.
8. Rizza RA, Mandarino LJ, Gerich JE: Cortisol-induced insulin resist-
ance in man: impaired suppression of glucose production
and stimulation of glucose utilization due to a postreceptor
detect of insulin action.  J Clin Endocrinol Metab 1982, 54:131-138.
9. van der Horst IC, Nijsten MW, Vogelzang M, Zijlstra F: Persistent
hyperglycemia is an independent predictor of outcome in
acute myocardial infarction.  Cardiovasc Diabetol 2007, 6:2.
10. Vogelzang M, Zijlstra F: Glucose metabolism and acute myocar-
dial infarction.  Eur Heart J 2006, 27(11):1264-1265.
11. Anderson RE, Brismar K, Barr G, Ivert T: Effects of cardiopulmo-
nary bypass on glucose homeostasis after coronary artery
bypass surgery.  Eur J Cardiothorac Surg 2005, 28(3):425-430.
12. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx
F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R:
Intensive insulin therapy in critically ill patients.  N Engl J Med
2001, 345(19):1359-1367.
13. Ingels C, Debaveye Y, Milants I, Buelens E, Peeraer A, Devriendt Y,
Vanhoutte T, Damme AV, Schetz M, Wouters PJ, van den Berghe G:
Strict blood glucose control with insulin during intensive
care after cardiac surgery: impact on 4-years survival,
dependency on medical care, and quality-of-life.  Eur Heart J
2006, 27(22):2716-2724.
14. van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C,
Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome bene-
fit of intensive insulin therapy in the critically ill: Insulin dose
versus glycemic control.  Crit Care Med 2003, 31(2):359-366.
15. Loef BG, Henning RH, Epema AH, Rietman GW, Van Oeveren W,
Navis GJ, Ebels T: Effect of dexamethasone on perioperative
renal function impairment during cardiac surgery with cardi-
opulmonary bypass.  Br J Anaesth 2004, 93(6):793-798.
16. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon
R:  European system for cardiac operative risk evaluation
(EuroSCORE).  Eur J Cardiothorac Surg 1999, 16:9-13.
17. Vogelzang M, van der Horst IC, Nijsten MW: Hyperglycaemic
index as a tool to assess glucose control: a retrospective
study.  Crit Care 2004, 8(3):R122-R127.
18. Morariu AM, Loef BG, Aarts LP, Rietman GW, Rakhorst G, van Oev-
eren W, Epema AH: Dexamethasone: benefit and prejudice for
patients undergoing on-pump coronary artery bypass graft-
ing: a study on myocardial, pulmonary, renal, intestinal, and
hepatic injury.  Chest 2005, 128(4):2677-2687.
19. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao
V, Borger MA: Hyperglycemia during cardiopulmonary bypass
is an independent risk factor for mortality in patients under-
going cardiac surgery.  J Thorac Cardiovasc Surg 2005, 130(4):1144.
20. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO,
Floten HS, Starr A: Continuous insulin infusion reduces mortal-
ity in patients with diabetes undergoing coronary artery
bypass grafting.  J Thorac Cardiovasc Surg 2003, 125(5):1007-1021.
21. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M,
Hippeläinen M, Juvonen T, Hartikainen J, Hakala T: Corticosteroids
for the prevention of atrial fibrillation after cardiac surgery:
a randomized controlled trial.  JAMA 2007, 297(14):1562-1567.
22. Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E: Effect of
mode of hydrocortisone administration on glycemic control
in patients with septic shock: a prospective randomized trial.
Crit Care 2007, 11:R21.
23. Hans P, Vanthuyne A, Dewandre PY, Brichant JF, Bonhomme V:
Blood glucose concentration profile after 10 mg dexameth-
asone in non-diabetic and type 2 diabetic patients undergo-
ing abdominal surgery.  Br J Anaesth 2006, 97(2):164-170.
24. Vogelzang M, Zijlstra F, Nijsten MW: Design and implementation
of GRIP: a computerized glucose control system at a surgical
intensive care unit.  BMC Med Inform Decis Mak 2005, 5:38.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral